Update on HCV Management in People Living with HIV and Other Key Populations

Kristen Marks, MD
Assistant Professor of Medicine
Cornell Clinical Trials Unit and Division of Infectious Diseases
Weill Cornell Medicine, New York, NY

CME VIDEOTop of page

About the Presenter: Top of page

Kristen Marks is an Assistant Professor of Medicine and ID Fellowship Program Director at Weill Cornell Medical College, where she conducts clinical trials related to HIV and HCV. She completed her Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (Cornell), where she focused clinical training and research on HIV and hepatitis virus infections, and also completed Weill Cornell's Master's Degree in Clinical Investigation. Dr. Marks took a leadership role advancing the treatment of hepatitis C in underserved populations at Cornell through clinical, education, and research activities. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections and includes studies of acute HCV as well as new treatment strategies for chronic HCV. Several research projects have focused specifically on HCV and drug use including an ongoing R01-funded study comparing HCV treatment delivery at a community syringe exchange program with usual care. She is the co-chair of an AIDS Clinical Trials Group (ACTG) multi-center study in development, currently serves on three ACTG hepatitis protocol teams, and is a member of the ACTG Hepatitis Transformative Science Group. Dr. Marks is a co-investigator in the Cornell HIV/AIDS Clinical Trials Unit and Center for Study of Hepatitis C, where she is site PI for several treatment studies and other protocols related to HCV. She is also co-chair of IDSA/AASLD’s joint guidelines panel for “Recommendations for testing, managing and treating hepatitis C” and a member of New York State’s HCV guidelines panel.

Learning Objectives: Top of page

At the completion of this educational session, learners will:
  • Be aware of updated HCV testing recommendations.
  • Know initial treatment recommendations for PLWH and other key populations.
  • Appreciate a strategy for initial HCV treatment simplification.

CME Information: Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ on December 11, 2018 and will terminate December 10, 2021.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
  • Accreditation Statement: Top of page

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

    The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

    Disclosure Statement: Top of page

    Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Kristen Marks (Presenter) had the following personal financial relationships in the prior 12 months with manufacturers of the products or services that may be presented in this CME activity: Research support from Gilead and BMS. Dr. Marks submitted her slides in advance for adequate peer review, and will support her presentation and clinical recommendations with the best available evidence from the medical literature.
  • Financial Support: Top of page

    This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.

    How to Obtain CME Credit: Top of page

    To obtain CME credit for this PRN program, please visit the PRN Courses Page at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.

    TranscriptionTop of page

    Yomistabus, hemistabus, shemistabus

    You must be logged in to post a comment. Login | Register